NovaCardia Report issue

For profit Phase 3
Founded: San Diego CA United States (2001)
Status: Acquired by Merck (2007)

Organization Overview

First Clinical Trial
2004
NCT00159627
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NovaCardia, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

rolofylline (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Renal Insufficiency (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1